ClinicalTrials.gg
CompletedNCT01347671Updated Jul 15, 2021

Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy

A Phase 2 interventional study of GRT6005 and GRT6005 in Pain and Diabetic Neuropathies, sponsored by Tris Pharma, Inc.. Completed at 22 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 201 studies in Pain with a site in Germany — 13 open to participants now, 14 under way, 8 of them phase 3. Pain · Germany.

Enrollment
54th of 162
189 · median 111
Started
2011
with 20 others
Phase 2
26 of 201
none open now
Registered
83rd of 201
by date

Among the 201 studies in Pain with a site in Germany, this one is the 54th largest by enrollment of the 162 interventional ones that give a count, is one of 21 that started in 2011, is one of 26 in phase 2, and was the 83rd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

13 of the 201 studies in Pain with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 201 studies in Pain with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this trial is to investigate the efficacy and safety of GRT6005 in patients with painful diabetic neuropathy.

03

Conditions studied

  • Pain
  • Diabetic Neuropathies

Keywords

  • analgesia
  • analgesics
  • pain
  • chronic pain
  • neuropathic pain
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, 18 to 75 years old.
  • Type 1 or type 2 diabetes.
  • Painful DPN symptoms and signs for at least 3 months.
  • Blood glucose controlled with medication.
  • Glycosylated not greater than 9.5 or 11%, country dependent.
  • Prior analgesic medication.
  • Average score of 4 or greater on the 11 point NRS during the last 3 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Impaired liver, cardiac or renal function.
  • Breastfeeding and pregnancy.
  • History of substance abuse, alcohol or medication.
  • Chronic gastrointestinal disease.
  • History of seizures and or epilepsy.
  • History or presence of .
  • Presence of painful medical conditions that are not due to diabetic neuropathy, e.g. rheumatoid arthritis.
  • Allergies to opioids, acetaminophen or of the medications.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
189 participants (actual)

Study arms

  • Active comparator
    25 µg GRT6005

    Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day

    Drug: GRT6005

  • Active comparator
    75 µg GRT6005

    Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day

    Drug: GRT6005

  • Active comparator
    200 µg GRT6005

    Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day

    Drug: GRT6005

  • Placebo comparator
    Matching Placebo

    Participants allocated to this treatment arm will receive a dose of matched placebo once a day.

    Drug: Matching Placebo

Interventions

  • 25µg/day once daily

  • 75 µg/day once daily

  • 200 µg/day once daily

  • DrugMatching Placebo

    Once daily

06

What researchers measure

Primary outcomes

  1. Change in mean daily pain intensity score

    Participants will be selected based on their medical history and clinical examination. Efficacy of the treatment (i.e., reduction of pain) will be evaluated with the 11-point numeric rating scale (NRS), where 0 represents no pain and 10 represents "pain as bad as you can imagine".

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Response measured in percentage change of pain intensity from baseline

    Time frame: End of 4 Weeks

  2. Changes in Quantitative Sensory Testing from baseline

    Time frame: Baseline, week 1 and week 4

  3. Neuropathic Pain Scale, changes from baseline

    Time frame: End of 4 weeks

  4. Short Form of the Brief Pain Inventory, changes from baseline

    Time frame: End of 4 weeks

  5. Leeds Sleep Evaluation Questionnaire

    Time frame: End of treatment

  6. Quality of Life Index -Short-Form-12®, from baseline

    Time frame: End of treatment

  7. Patient's Global Impression of Change

    Time frame: End of treatment

  8. Quality of Life EuroQoL-5 Dimension score, change from baseline

    Time frame: End of 4 weeks

  9. Rescue medication use

    Time frame: End of 4 weeks

  10. Clinical Opioid Withdrawal Scale

    Time frame: End of 4 weeks

  11. Plasma concentration

    Time frame: End of 4 weeks

07

Study locations

22 sites
  • Site 4502
    Sofia, 1431, Bulgaria
  • Site 4112
    Aschaffenburg, 63739, Germany
  • Site 4109
    Bad Oeynhausen, 32545, Germany
  • Site 4101
    Berlin, 10117, Germany
  • Site 4110
    Berlin, 13125, Germany
  • Site 4111
    Dresden, 01307, Germany
  • Site 4107
    Hamburg, 20253, Germany
  • Site 4117
    Hamburg, 22587, Germany
  • Site 4108
    Hannover, 30159, Germany
  • Site 4104
    Hannover, 30167, Germany
  • Site 4115
    Heidelberg, 69120, Germany
  • Site 4106
    Kiel, 24119, Germany
  • Site 4102
    Lübeck, 23562, Germany
  • Site 4103
    Mainz, 55116, Germany
  • Site 4105
    Münster, 48145, Germany
  • Site 4113
    Schwerin, 19055, Germany
  • Site 4116
    Wangen, 88239, Germany
  • Site 4405
    Bucuresti, 010496, Romania
  • Site 4402
    Bucuresti, 011025, Romania
  • Site 4407
    Sibiu, 550166, Romania
  • Site 4406
    Timisoara, 300594, Romania
  • Site 4401
    Târgu-Mureş, 540139, Romania
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2011
First posted
May 4, 2011
Start
May 2011
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01347671
Lead sponsor
Tris Pharma, Inc.
Collaborators
Forest Laboratories
Responsible party
Sponsor
First posted
May 4, 2011
Start date
May 2011
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Jul 15, 2021

Study contacts

Thomas Forst, Prof. Dr.
principal investigator · ikfe GmbH, Institut for Klinische Forschung und Entwicklung, Parcusstr. 8, 55116 Mainz, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion